Boston Scientific Shares Face Valuation Scrutiny Following Guidance Cut

Boston Scientific Corporation is facing heightened scrutiny over its valuation following a sharp 56.4% decline in its share price over the past year. Yahoo Finance Singapore reported that the medical device maker's shares recently traded at $44.70, carrying an 18.5x price-to-earnings ratio. While the firm generated roughly $3.3b in free cash flow over the trailing twelve months, investors are questioning whether ongoing spending can sustain projected cash growth into the mid $4b range by 2030.

The valuation focus follows third-quarter 2026 financial results that fell short of earlier expectations. Boston Scientific posted quarterly revenues of $5.14 billion, representing organic sales growth of 1.5% compared to prior guidance of 3%-5%. The company attributed an eight-business-day global network disruption from an August cybersecurity incident to a reduction of approximately 300 basis points in organic sales growth. Adjusted earnings per share dropped 3% year over year to 73 cents, missing management's earlier projection of 80-82 cents.

Performance across the company's segments varied widely during the quarter. Neuromodulation sales increased 13% and Interventional Cardiology grew 19%. In contrast, previously strong franchises showed weakness, with Electrophysiology sales dropping 5% and WATCHMAN product sales declining 6%. Adjusted gross margin decreased 300 basis points to 68%, while adjusted operating margin shrank 150 basis points to 26.5% due to operational and absorption challenges tied to the disruption.

Following these results, management lowered its full-year 2026 organic sales growth guidance to approximately 3.75% from an earlier forecast of 5%-6%. Adjusted earnings per share expectations were also cut to $3.16-$3.18, down from $3.28-$3.32. For the final quarter of 2026, the company projects reported and organic sales to decline between 1%-3%, accompanied by adjusted earnings of 77-79 cents per share.

Looking further ahead, management cautioned that 2027 is expected to mark the trough of the current cycle, with meaningful recovery delayed until 2028 when products like FARAWAVE Ultra are anticipated to launch. Zacks Investment Research downgraded the stock to a Rank #5 (Strong Sell), citing negative revisions to earnings estimates. Meanwhile, the company continues advancing clinical programs, including the SIMPLAAFY trial for the WATCHMAN FLX Pro device, and is working to finalize its pending acquisition of Penumbra.